Determinatori kliničkih ishoda u obolelih od hroničnih artritisa i sistemskih bolesti vezivnog tkiva: fokus pandemija COVID-19
Sažetak
Uvod. Rana dijagnoza i terapija poboljšavaju kliničke
ishode, naročito kod hroničnih artritisa (HA) i sistemskih bolesti
vezivnog tkiva (SBVT). Zahvaljujući kliničkim istraživanjima
od 1990. godine, inovativnim lekovima sačuvano je
55 miliona godina života. Pandemija COVID-19 donela je
medicinske izazove u reumatologiji.
Cilj istraživanja je bio da se kod obolelih od HA i/ili
SBVT ispita rano uspostavljanje dijagnoze, vreme uvođenja
inovativne terapije, učešće u kliničkim istraživanjima, uticaj
pola, starosti i lečenje kortikosteroidima na stopu hospitalizacije
usled COVID-19 infekcije.
Metod. U novembru 2022. godine sproveli smo studiju
preseka kod obolelih od HA i/ili SBVT koristeći ’’online’’
upitnik. Prvi deo analiziranih pitanja odnosio se na socio-demografske
karakteristike i podatke vezane za reumatsku
bolest - reumatoidni artritis (RA)/ostale reumatske bolesti,
a drugi deo na COVID-19. Podaci su analizirani deskriptivnom
statistikom i Pirsonovim Hi-kvadrat testom korišćenjem
SPSS 29.
Rezultati. Od ukupno 176 ispitanika, RA je imalo
60,8%. Vreme od prvih simptoma do dijagnoze bilo je duže
od dve godine. U prvih šest meseci češće se dijagnostikovao
RA (p < 0,05 - muškarci). Inovativnu terapiju koristilo je
59,7% ispitanika. Većini obolelih od RA inovativna terapija
je uvedena nakon pet godina, kasnije u odnosu na ostale HA
(p < 0,05 - žene). U kliničkim istraživanjima učestvovalo je
23,3% ispitanika, više oboleli od RA (p < 0,05 - žene). Kortikosteroidna
terapija uticala je na višu stopu hospitalizacije
tokom COVID-19 infekcije (p < 0,05 - žene).
Zaključak. Muškarcima obolelim od RA brže se postavlja
dijagnoza, dok žene obolele od RA imaju veće učešće u
kliničkim istraživanjima, ali kasnije uvođenje inovativne
terapije. Upotreba glukokortikoida u lečenju HA i SBVT povećava
rizik za hospitalizaciju usled infekcije COVID-19.
Reference
de Thurah A, Bosch P, Marques A, Meissner Y, Mukhtyar CB, Knitza J, et al. 2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases. Ann Rheum Dis 2022;81(8):1065–71.
Fouad AM, Elotla SF, Elkaraly NE, Mohamed AE. Impact of COVID-19 Pandemic on Patients with Rheumatic and Musculoskeletal Diseases: Disruptions in Care and Self-Reported Outcomes. J Patient Exp 2022;9:23743735221102678.
Brussels declaration on rheumatic and musculoskelatal diseases [homepage on the Internet]. [update 2023 June 16; cited 2023 July 25]. Available from: https://www.eular.org/web/static/lib/pdfjs/web/viewer.html?file=https://www.eular.org/document/download/447/317b9f35-479d-48db-9b67-70529b91fad8/447
Tarannum S, Widdifield J, Wu CF, Johnson SR, Rochon P, Eder L. Understanding sex-related differences in healthcare utilisation among patients with inflammatory arthritis: a population-based study. Ann Rheum Dis 2023;82(2):283–91.
Stack RJ, Nightingale P, Jinks C, Shaw K, Herron-Marx S, Horne R, et al. DELAY study syndicate. Delays between the onset of symptoms and first rheumatology consultation in patients with rheumatoid arthritis in the UK: an observational study. BMJ Open 2019;9(3):e024361.
Xiang L, Low AHL, Leung YY, Fong W, Gandhi M, Yoon S, et al. Interval between symptom onset and diagnosis among patients with autoimmune rheumatic diseases in a multi-ethnic Asian population. Int J Rheum Dis 2021;24(8):1061–70.
Lichtenberg FR. Has medical innovation reduced cancer mortality? CESifo Economic Studies 2014;60(1):135–77.
Sandhu VK, Duro T, Kamboj A, Salto L, Chiruvolu N. Barriers to Enrollment in Rheumatology Research: Who, What, Where, When, and Why? Cureus 2022;14(7):e27235.
Vogt S, Tarner IH, Müller-Ladner U, König R. Motivation for and barriers to participation in clinical trials from the perspective of patients with rheumatic diseases and chronic musculoskeletal pain. Open Rheumatol J 2018;12(1):332–45.
Djordevic S, Kosanovic M. POS0193-PARE TIME TO RESEARCH -STRENGTHENING PATIENT RESEARCH PARTNER 2022. Annals of the Rheumatic Diseases 2023;82(1):322.
Bijlsma JW. EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs. Ann Rheum Dis 2021;80(4):411–12.
Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. Arthritis Rheumatol 2021;73(10):e60-75.
Djordevic S, Lapčević M. POS1571-PARE ONLINE COUNSELLING FOR PATIENTS WITH ARTHRITIS. Annals of the Rheumatic Diseases 2022;81(Suppl 1):1132.
Andreica I, Roman I, Redeker I, Baraliakos X, Braun J, Kiltz U. Facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study. RMD Open 2023;9(2):e002875.
Aboud FM, Hussein RS, Hassan RM. Safety and reported adverse effects of coronavirus disease-2019 (COVID-19) vaccines in patients with rheumatic diseases. Egypt Rheumatol 2023;45(2):133 –7.
Hasseli R, Mueller-Ladner , Hoyer BF, Krause A, Lorenz HM, Pfeil A, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open 2021;7(1):e001464.
Roseti L, Grigolo B. COVID-19 and rheumatic diseases: A mini-review. Front Med (Lausanne) 2022;9:997876.
Kawazoe M, Kihara M, Nanki T. Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists. Pharmaceuticals (Basel) 2021;14(12):1256.
Lapčević M, Prvanov D, Đorđević S. Quality of life estimation in patients suffering from chronic rheumatic diseases. Opšta medicina 2010;16(3-4):113–23.
Lapčević M, Vojinović J, Damjanov N, Šefik Bukilica M, Ilić T, Tomić Lučić A, et al. Priključi se zadnji je voz - uoči rano. Acta rheumatologica Belgradensia 2018;48(1):109–13.
Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE. Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky. Curr Rheumatol Rep 2018;20(6):35.
EFPIA Market Access Delays Analysis. [homepage on the Internet]. [update 2023 June 18; cited 2023 July 26]. Available from: https://www.efpia.eu/media/412416/market-access-delays-2017-final-140318.pdf
Lapčević M, Vuković M, Gvozdenović BS, Mioljević V, Marjanović S. Socioeconomic and therapy factor influence on self-reported fatigue, anxiety and depression in rheumatoid arthritis patients. Rev Bras Reumatol Engl Ed 2017;57(6):545–56.
Kedra J, Granger B, Emilie S, Gaujoux-Viala C, Rat AC, Combe B, et al. Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIR. Joint Bone Spine 2021;88(1):105060.
Hyrich KL, Machado PM. Rheumatic disease and COVID-19: epidemiology and outcomes. Nat Rev Rheumatol 2021;17(2):71–2.
Rutter M, Lanyon PC, Grainge MJ, Hubbard R, Bythell M, Stilwell P, et al. COVID-19 infection, admission and death and the impact of corticosteroids amongst people with rare autoimmune rheumatic disease during the second wave of covid-19 in England: results from the RECORDER Project. Rheumatology (Oxford) 2023:kead150.
Grainger R, Kim AHJ, Conway R, Yazdany J, Robinson PC. COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nat Rev Rheumatol 2022;18(4):191–204.
Imunizacija imunokompromitovanih pacijenata. [homepage on the Internet]. [update 2023 June 15; cited 2023 July 27]. Available from: https://www.ors.rs/storage/files/Imunizacija%20imunokompromitovanih%20pacijenata%20final.pdf
Montero F, Martínez-Barrio J, Serrano-Benavente B, González T, Rivera J, Molina Collada J, Castrejón I, et al. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int 2020;40(10):1593–8.
De Cock D, Meyfroidt S, Joly J, Van der Elst K, Westhovens R, Verschueren P. CareRA study group*. A detailed analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis patients. Scand J Rheumatol 2014;43(1):1–8.
Sva prava zadržana (c) 2024 Irena Pušica, Mirjana Lapćević, Stojanka Ratković, Marina Manić, Mirjana Arapović
Ovaj rad je pod Creative Commons Autorstvo-Nekomercijalno-Deli pod istim uslovima 4.0 međunarodnom licencom.
Autori zadržavaju autorska prava nad objavljenim člancima, a izdavaču daju neekskluzivno pravo da članak objavi, da u slučaju daljeg korišćenja članka bude naveden kao njegov prvi izdavač, kao i da distribuira članak u svim oblicima i medijima.